Daily Intelligence Brief
Hair Relaxer Overtakes Depo-Provera in Federal Filing Surge as Massive Daubert Deadline Looms
LexGenius tracked 61 new mass tort filings yesterday, with pharmaceutical and product liability claims continuing to dominate federal dockets. The Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) reclaimed its position as the high-volume leader with 15 new suits, spearheaded by Morgan & Morgan PA and DiCello Levitt LLP. This influx of new inventory comes as the litigation—overseen by U.S. District Judge Mary M. Rowland in the Northern District of Illinois—enters its most critical phase to date: a pending 100-page Daubert challenge from defendants targeting all ten of the plaintiffs' general causation experts. Close behind, the Depo-Provera Products Liability Litigation (MDL 3140) added 12 new claims, driven by Rubenstein Law PA and Weitz & Luxenberg PC as the docket accelerates toward 5,000 actions. Centralized before U.S. District Judge M. Casey Rodgers in the Northern District of Florida, the Depo-Provera litigation centers on allegations that Pfizer's contraceptive injection causes intracranial meningioma brain tumors. Meanwhile, institutional abuse claims saw a notable expansion as Parafinczuk Wolf PA initiated a block of 3 new actions in MDL 3166 (In re: Roblox Corporation Child Sexual Exploitation and Assault Litigation). Centralized before Chief U.S. District Judge Richard Seeborg in the Northern District of California, the surge signals a broadening of platform-based corporate liability theories.Character.ai Settlements Trigger Shift Toward State AG "Deceptive Practice" Enforcement
Following a series of landmark mediated settlements in early 2026—including the high-profile Florida wrongful death suit involving teen Sewell Setzer III, which named both Character Technologies and Google as co-defendants—the legal focus on AI Chatbot Litigation has shifted from individual torts toward aggressive state-level consumer protection enforcement. Kentucky Attorney General Russell Coleman recently initiated a major lawsuit against Character Technologies, leaning heavily on the Kentucky Consumer Protection Act. Coleman alleges the platform knowingly bypassed safety filters to expose minors to sexual content and self-harm triggers. Simultaneously, Texas Attorney General Ken Paxton has opened a broad investigation into the company's "mental health" chatbots. Paxton is wielding the Texas Data Privacy and Security Act (TDPSA) to argue that AI agents impersonating licensed professionals constitute deceptive trade practices under state law. These actions, coupled with the platform's recent "moderation wave" that purged thousands of characters to mitigate liability, indicate a transition toward strict product liability theories targeting AI design defects.EPA Proposes Major Rollback of Ethylene Oxide Standards Amid Supply Chain Concerns
The Ethylene Oxide (EtO) Litigation landscape faces a significant regulatory pivot following the EPA's March 17, 2026, proposal to rescind and revise the stringent emission standards finalized by the Biden administration in 2024. The agency, under Administrator Lee Zeldin, is moving to repeal tighter risk-based limits for commercial sterilizers—which carried an original April 2026 compliance deadline—in favor of less restrictive technology-based requirements. The EPA now asserts that it overstepped its statutory authority under Clean Air Act Section 112(f)(2) by conducting a second "residual risk review" that was not legally permitted. While the proposal aims to prevent medical device supply chain disruptions, it has triggered immediate legal challenges from environmental advocacy groups in the D.C. Circuit, who argue the rollback leaves fenceline communities at an "unacceptable" risk of cancer exposure. Notably, the rollback rescinds the requirement for facilities to implement Continuous Emissions Monitoring Systems (CEMS), allowing them to revert to parametric monitoring. For plaintiff firms, this regulatory softening increases the weight of state-court personal injury trials, as the lack of continuous tracking may strengthen "failure-to-warn" claims. The public comment period for the rollback remains open through May 1, 2026.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
